Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan

Hattori, Junko; Shiino, Teiichiro; Gatanaga, Hiroyuki; Yoshida, Shigeru; Watanabe, Dai; Minami, Ryoji; Sadamasu, Kenji; Kondo, Makiko; Mori, Haruyo; Ueda, Mikio; Tateyama, Masao; Ueda, Atsushi; Kato, Shingo; Ito, Toshihiro; Oie, Masayasu; Takata, Noboru; Hayashida, Tsunefusa; Nagashima, Mami; Matsuda, Masakazu; Ibe, Shiro; Ota, Yasuo; Sasaki, Shogo; Ishigatsubo, Yoshiaki; Tanabe, Yoshinari; Koga, Ichiro; Kojima, Yoshiyuki; Yamamoto, Masahiro; Fujita, Jiro; Yokomaku, Yoshiyuki; Koike, Takao; Shirasaka, Takuma; Oka, Shinichi; Sugiura, Wataru

doi:10.1016/j.antiviral.2010.07.008

Cited by 52 publications

(63 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the specimens collected at NMC, we reviewed pol PR-RT sequences collected in the Japanese Drug Resistance HIV-1 Surveillance Network. 18 Among 3,899 cases classified as B in the region reviewed, five cases (three from Kanto and two from Hokuriku Areas, see Supplementary Fig. S1) were teased out as probable AE/B recombinant cases, and their sequences were analyzed along with the 13 NMC cases.…”

Section: Samplementioning

confidence: 99%

“…15 The major circulating HIV-1 subtype in Japan has been B, which is genetically related to the strain circulating in North America, 16,17 followed by AE, with prevalences of 87.9% and 8.4%, respectively. 18 These two strains have distinct epidemiological characteristics; B predominates in men who have sex with men (MSM), whereas AE is observed mostly in heterosexuals engaging in high-risk sex. 18 However, the distinction between these two populations is becoming blurred as increasing numbers of AE cases have also been found in MSM.…”

Section: Introductionmentioning

confidence: 99%

“…18 These two strains have distinct epidemiological characteristics; B predominates in men who have sex with men (MSM), whereas AE is observed mostly in heterosexuals engaging in high-risk sex. 18 However, the distinction between these two populations is becoming blurred as increasing numbers of AE cases have also been found in MSM. 16,19 Therefore, the chance of recombination between the two strains is increasing in Japan.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan

Hosaka

Fujisaki

Masakane

et al. 2016

AIDS Research and Human Retroviruses

Self Cite

View full text Add to dashboard Cite

The major circulating HIV-1 strains in Japan have been subtype B (B) followed by CRF01_AE (AE) in newly diagnosed HIV/AIDS cases. These two subtypes have distinct epidemiological characteristics; B predominates in men who have sex with men, while AE is observed mostly in heterosexuals engaging in high-risk sex. However, transmission networks of these two high-risk populations appear to be crossing over and diffusing. Here we report the emergence of previously unidentified HIV-1 AE/B recombinants in Japan. We initially identified 13 cases with discordant subtyping results with AE (gag MA)/B ( pol PR-RT)/AE (env C2V3) by molecular phylogenetic analysis of 1,070 cases who visited Nagoya Medical Center from 1997 to 2012. Genetic characterization of full-length sequences demonstrated that they shared an identical recombinant structure, and was designated as CRF69_01B by the Los Alamos HIV National Laboratory. By reviewing gag, pol, and env sequences collected in the Japanese Drug Resistance HIV-1 Surveillance Network, we found five other CRF69_01B probable cases from different areas in Japan, suggesting that the strain is transmitted widely throughout the country. The time of the most recent common ancestor analyses estimated that CRF69_01B emerged between 1991 and 1995, soon after AE was introduced from neighboring countries in the mid-1990s. Understanding the current epidemic strains is important for the diagnosis and treatment of HIV/AIDS, as well as for the development of globally effective HIV vaccines.

show abstract

Section: Samplementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan

Hosaka

Fujisaki

Masakane

et al. 2016

AIDS Research and Human Retroviruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…6 However, TDR was also detected among therapynaive patients in other Asian countries. In Japan, the prevalence of TDR increased from 5.9% in 2003 to 8.3% in 2008 in therapy-naive HIV-1 patients 7 ; it increased to 5% in Vietnam,8 3% in Korea, 9 and 4.3% in South Korea. 10 Though the prevalence of TDR was relatively lower in China, it could threaten the public health of Chinese, since it could compromise the effectiveness of virologic suppression and successful treatment.…”

Section: Introductionmentioning

confidence: 99%

Transmitted Antiretroviral Drug Resistance and Thumb Subdomain Polymorphisms Among Newly HIV Type 1 Diagnosed Patients Infected with CRF01_AE and CRF07_BC Virus in Guangdong Province, China

Yang

Liu

Zhang

et al. 2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

The aim of this study was to elucidate the prevalence of transmitted drug-resistant (TDR) mutations and reverse transcriptase (RT) thumb subdomain polymorphisms in CRF01_AE and CRF07_BC virus among newly diagnosed, therapy-naive HIV-1 patients in Guangdong Province, China. One hundred and sixty-four samples were collected in the Guangzhou Eighth People's Hospital. The entire protease gene and 300 codons of the entry part of the reverse transcriptase were amplified and sequenced. Furthermore, genotypic drug resistance, polymorphisms, and their phylogeny were analyzed. According to eligibility criteria, seven samples were excluded, and 119 of 157 (75.8%) samples (84 CRF01_AE and 35 CRF07_BC) were amplified and sequenced successfully. The prevalence of TDR identified in the present study was 6.7% [8/119, 95% confidence interval (CI) 1.8-11.6%]. Three major resistance mutations, K103N, M184V, and Y188L, each of which caused more than one drug resistance, appeared in only two patients; the prevalence [1.7 % (2/119)] was relatively low. Until now, this is the first observation of the five newly identified accessory mutations, V35T, K43E, V60I, K122E, and E203D, and seven thumb subdomain polymorphisms, A272P, K277R, K281R, T286A, E291D, V292I, and I293V, in the RT gene in China. These findings provide useful information for guidance on the antiretroviral therapy (ART) policy in China where therapeutic options are still limited.

show abstract

“…Each patient's actual body weight was used for the calculation of eGFR. At screening, a genotypic drug resistant test and screening for the HLA-B*5701 allele were permitted but not required because the prevalence of both the drug resistant virus and the HLA-B*5701 allele are low in Japanese patients (7,25). Medical history, including a history of AIDS-defining illnesses and other comorbidities, was also collected.…”

Section: Study Patientsmentioning

confidence: 99%

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial

et al. 2013

Self Cite

View full text Add to dashboard Cite

Objective To compare the efficacy and safety of fixed-dose abacavir/lamivudine (ABC/3TC) and tenofovir/ emtricitabine (TDF/FTC) with ritonavir-boosted atazanavir (ATV/r) in treatment-naïve Japanese patients with HIV-1 infection. Methods A 96-week multicenter, randomized, open-label, parallel group pilot study was conducted. The endpoints were times to virologic failure, safety event and regimen modification. Results 109 patients were enrolled and randomly allocated (54 patients received ABC/3TC and 55 patients received TDF/FTC). All randomized subjects were analyzed. The time to virologic failure was not significantly different between the two arms by 96 weeks (HR, 2.09; 95% CI, 0.72-6.13; p=0.178). Both regimens showed favorable viral efficacy, as in the intention-to-treat population, 72.2% (ABC/3TC) and 78.2% (TDF/ FTC) of the patients had an HIV-1 viral load <50 copies/mL at 96 weeks. The time to the first grade 3 or 4 adverse event and the time to the first regimen modification were not significantly different between the two arms (adverse event: HR 0.66; 95% CI, 0.25-1.75, p=0.407) (regimen modification: HR 1.03; 95% CI, 0.33-3.19, p=0.964). Both regimens were also well-tolerated, as only 11.1% (ABC/3TC) and 10.9% (TDF/FTC) of the patients discontinued the allocated regimen by 96 weeks. Clinically suspected abacavir-associated hypersensitivity reactions occurred in only one (1.9%) patient in the ABC/3TC arm. Conclusion Although insufficiently powered to show non-inferiority of viral efficacy of ABC/3TC relative to TDF/FTC, this pilot trial suggested that ABC/3TC with ATV/r is a safe and efficacious initial regimen for HLA-B*5701-negative patients, such as the Japanese population.

show abstract

Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan

Cited by 52 publications

References 33 publications

HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan

HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan

Transmitted Antiretroviral Drug Resistance and Thumb Subdomain Polymorphisms Among Newly HIV Type 1 Diagnosed Patients Infected with CRF01_AE and CRF07_BC Virus in Guangdong Province, China

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial

Contact Info

Product

Resources

About